Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

NCT06476184 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Carboplatin
DRUG: Paclitaxel

Sponsor

ARCAGY/ GINECO GROUP

Collaborators

[object Object]